About: http://data.cimple.eu/news-article/ec6091e155f3ef29a7e1ed83f7141a1fc7822c957f37d91324182f88     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • FOR MEDICAL BUSINESS/TRADE MEDIA ONLY Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all Mundipharma strategic and operational matters globally, focusing on seamless execution of the 2020-2023 Business Plan. Speaking of the appointment, Jacques Theurillat, Chairman, said "Marc is a highly proven pharmaceutical executive with a strong track record at leading pharma companies such as Schering-Plough, Merck & Co, Takeda and Allergan. He is widely recognised for his expertise in business change and transformation and joins us at an important moment as we continue our evolution as an organization. I wish him every success in his role with us." Marc is joining Mundipharma from Allergan International, where he was the President and EVP, International Business. He brings more than 30 years cross-functional experience in the pharmaceutical Industry with expertise spanning commercial, marketing, business development and management. Marc holds a Bachelor in Physiotherapy degree from Katholieke Universiteit in Leuven, Belgium. "I am proud and delighted to be joining Mundipharma at this pivotal time," Princen said. "I see a genuine opportunity to help build a new and exciting future for the organisation as it continues on its transformation journey." -Ends- Notes to editors: About the Mundipharma network Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East. We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare. For further information by geographic region please go to www.mundipharma.com (Europe); (Canada) and www.mundipharma.com.sg (other ex-US markets). View source version on businesswire.com: Contact For further information please contact: Helen Rae helenrae@makarahealth.com T: +44 (0) 23 81 247 327 Rob Gallo rob.gallo@mundipharma.com T: +44 (0) 7773 009578 © 2020 Business Wire, Inc. Disclaimer: This material is not an AFP editorial material, and AFP shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.
schema:headline
  • Press Release from Business Wire: Mundipharma
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software